
Investors should consider Oscar Health (OSCAR) as a high-conviction growth play, given its massive 53% year-over-year revenue growth and a valuation that remains "dirt cheap" relative to its peers. The company is aggressively targeting the gig economy and employer-sponsored ICHRAs, positioning it to capture a more profitable and less regulated segment of the healthcare market. Management’s conservative Medical Loss Ratio (MLR) guidance of 83% suggests a high likelihood of future earnings beats if they maintain their current operational efficiency. OSCAR is also leveraging AI agents to structurally lower costs and improve margins, a technological edge that traditional insurers like UnitedHealth Group (UNH) may struggle to replicate quickly. With a target of $19 billion in revenue by 2026, this stock offers a significant contrarian opportunity for those looking to diversify into high-growth healthcare.

By @BeatTheDenominator